Disseminated molluscum contagiosum in a patient with chronic plaque psoriasis taking methotrexate

Lim, Kar Seng; Foo, Christopher C. I.

doi:10.1111/j.1365-2230.2007.02493.x

Cited by 21 publications

(20 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The occurrence of multiple MCs during treatment with PSL, MTX, and biologics has been reported [1][2][3][4][5][6], and a few cases of multiple MCs in patients with RA have also been seen [5,6]. A number of studies have shown immunologic dysfunction in RA.…”

Section: Discussionmentioning

confidence: 92%

Eruptive molluscum contagiosums in a patient with rheumatoid arthritis and lung cancer

et al. 2010

View full text Add to dashboard Cite

A 67-year-old woman with rheumatoid arthritis (RA) treated with systemic prednisolone and methotrexate over 20 years developed eruptive molluscum contagiosums on the trunk and extremities. Investigation revealed lung cancer 2 years later. Newly development of molluscum contagiosums ceased after the surgical operation of lung cancer. Immunologic dysfunctions have been shown in RA, and especially patients under long-term methotrexate therapy are susceptible to miscellaneous skin conditions. Eruptive molluscum contagiosums are induced in association with hematologic malignancies such as lymphoma, leukemia, and HIV infection; however, it is important to investigate internal malignancies, not only hematologic malignancies but also solid cancers, when patients with RA under immunosuppressive therapies presented eruptive or disseminated molluscum contagiosums.

show abstract

Section: Discussionmentioning

confidence: 92%

Eruptive molluscum contagiosums in a patient with rheumatoid arthritis and lung cancer

et al. 2010

View full text Add to dashboard Cite

show abstract

“…[11,12], prednisone [13], anti-TNFα [12,14] ont été décrits dans la littérature. Cursiefen et al [12] rapportent notamment le cas d'un patient traité depuis plusieurs années par méthotrexate et prednisone ayant présenté des lésions cutanées bilatérales de MC au niveau de la paupière, après la mise en place d'un traitement par anti-TNFα.…”

Section: Fig 2 Histological Section (Hes Staining)unclassified

“…Cependant, aucun cas sous tocillizumab n'est rapporté, ce qui peut s'expliquer par le fait que ce médicament est plus récent. Enfin, Lim et al [11] ne recommandent pas l'arrêt du traitement si ce dernier est efficace.…”

Section: Fig 2 Histological Section (Hes Staining)unclassified

Molluscum contagiosum de la muqueuse orale : cas clinique et revue de la littérature

Pédeboscq

Catros

Lepreux

et al. 2015

Med Buccale Chir Buccale

View full text Add to dashboard Cite

RésuméAbstract -Molluscum contagiosum of the oral mucosa: case report and literature review. Introduction : Molluscum contagiosum (MC) is a viral cutaneous infection which is passed on by direct or indirect contact. It commonly affects children, but oral mucosa manifestations are rare. Observation: The case of a 70-year-old patient, affected by rheumatoid polyarthritis treated by immunomodulators, and presenting MC of the oral mucosa, is reported. Discussion: In a systematic review of the literature, 7 cases of MC presenting the same oral manifestations have been described. The clinical features differ between immunocompetent and immunosuppressed patients. Conclusion: In cases of recurring MC, local surgical treatment and regular follow-up must be proposed to the patient.

show abstract

“…Mucocutaneous side‐effects include pruritus, pain, urticaria, mild reversible alopecia, ecchymosis, acute ulcerations of psoriatic lesions, reactivation of phototoxic responses and rarely, toxic epidermal necrolysis‐like dermatoses . An increased incidence of cutaneous infections such as disseminated molluscum contagiousum has also been reported . When given within a few days of ultraviolet (UV) irradiation, MTX may reactivate an acute sunburn response, also known as UV recall, photo recall or photodermatitis reactivation .…”

Section: Methotrexatementioning

confidence: 99%

Systemic methotrexate therapy for psoriasis: past, present and future

Dogra

Mahajan

2013

Clin Exp Dermatol

View full text Add to dashboard Cite

Methotrexate (MTX) has remained the backbone of the treatment for moderate to severe psoriasis ever since its first use nearly half a century ago. Over the years, its high efficacy, low cost, relative ease of administration and usefulness in concomitant psoriatic arthritis have contributed in making MTX the drug of choice in managing severe psoriasis. Although the majority of patients achieve remission of disease activity with MTX, a significant proportion may experience mild and transient adverse effects. From time to time, various guidelines on the use of MTX have correctly and adequately stressed the need for strict monitoring of haematological and hepatic adverse events. Over the years, the safe total cumulative dose of MTX (above which the risk of developing liver fibrosis is significantly increased) has been raised. Simultaneously, there has been an increased emphasis on developing noninvasive tests such as scanning and serum biomarker assays for detecting early liver fibrosis, in order to obviate the need for liver biopsy. However, the recent discovery and subsequent proliferating use of biological response modifiers has gradually shifted the focus away from MTX, despite it still being the most commonly prescribed drug for psoriasis worldwide. The aim of this review is to present a detailed account of MTX therapy and its use in psoriasis, along with its current relevance in disease management in the evolving era of biological drugs.

show abstract

Disseminated molluscum contagiosum in a patient with chronic plaque psoriasis taking methotrexate

Cited by 21 publications

References 5 publications

Eruptive molluscum contagiosums in a patient with rheumatoid arthritis and lung cancer

Eruptive molluscum contagiosums in a patient with rheumatoid arthritis and lung cancer

Molluscum contagiosum de la muqueuse orale : cas clinique et revue de la littérature

Systemic methotrexate therapy for psoriasis: past, present and future

Contact Info

Product

Resources

About